Frontier Pharma – Rheumatoid Arthritis: Identifying and Commercializing First-in-Class Innovation

ALBANY, New York, December 31, 2013 /PRNewswire/ –

- Market Analysis, Size, Share, Growth, Trends And Forecast Research Report Available Online By ResearchMoz.us

ResearchMoz.us includes new market research report “Frontier Pharma – Rheumatoid Arthritisto its huge collection of research reports.

Summary: Researchmoz presents this most up-to-date research on Frontier Pharma – Rheumatoid Arthritis (http://www.researchmoz.us/frontier-pharma-rheumatoid-arthritis-identifying-and-commercializing-first-in-class-innovation-report.html). Research has released a new pharmaceutical report, “Frontier Pharma: Rheumatoid Arthritis Identifying and Commercializing First-in-Class Innovation”. This highly competitive market is saturated with multiple targeted monoclonal Antibody (mAb) therapies and small molecules, yet more of these treatments are expected to enter the market over the next few years. Despite this, the current developmental pipeline is highly innovative beyond these me-too products and incremental innovations and promises a number of first-in-class products across all stages. These new developments are driven by improvements in the understanding of signaling pathways and underlying disease mechanisms of Rheumatoid Arthritis (RA). These highly innovative products are expected to increase the diversity of available products, in terms of mechanism of action over the coming decade and are likely to have a significant impact on the dynamics of the clinical and commercial landscape.

The market is also characterized by high activity in licensing and co-development deals. In particular, there is sustained commercial interest in pipeline biologic therapies with a range of molecular targets. There is also considerable interest in small molecule inhibitors of intracellular kinesis despite their clinical performances not being as well established as biologics or mAbs.

Scope

  • The report analyzes the RA pipeline and strategic alliance landscape with particular emphasis on first-in-class programs.
  • A brief introduction to RA, including symptoms, path physiology, and an overview of the pharmacotherapy
  • Highlights of the changing molecular target landscape between marketed and pipeline products with particular focus on innovation
  • A comprehensive review of first-in-class pipeline therapies; the pipeline is analyzed by Phase distribution, molecule type, molecular target, and administration route
  • Identification and assessment of first-in-class molecular targets highlighting early-stage programs with clinical utility that has yet to be evaluated, as well as an in-depth literature review of novel molecular targets
  • Assessment of the licensing and co-development deals for RA therapeutics

Reasons to buy

  • The report will assist business development strategies of companies who wish to develop RA therapies with improved benefits to existing treatments. In addition, this report will be of interest to companies seeking to expand pipeline portfolios through licensing agreements and co-development deals allowing them to 
  • Understand the overall focal shifts in therapeutic molecular targets of RA treatments
  • Identify first-in-class product development and understand the therapeutic and commercial prospects of first-in-class developmental programs based on available animal model data
  • Assess the value of products benchmarked against licensed and co-developed therapeutic programs 
  • Spot first-in-class programs that are potentially available for licensing and co-development deals

Related & Recently Added Reports by Researchmoz.us to its store.

Global and China Syringes Industry 2013 Market Research Report (http://www.researchmoz.us/global-and-china-syringes-industry-2013-market-research-report-report.html  ) The report firstly introduced Syringes basic information included Syringes definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, Syringes industry policy and plan, Syringes product specification, manufacturing process, cost structure etc. then statistics Global and China key manufacturers Syringes capacity production cost price profit production value gross margin etc information, and Global and China Syringes capacity production market share supply demand shortage import export consumption etc data statistics, and Syringes 2009-2014 capacity production price cost profit production value gross margin etc information.

Global and China Prefilled Syringes Industry 2013 Market Research Report (http://www.researchmoz.us/global-and-china-prefilled-syringes-industry-2013-market-research-report-report.html  ) The report firstly introduced Prefilled Syringes basic information included Prefilled Syringes definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, Prefilled Syringes industry policy and plan, Prefilled Syringes product specification, manufacturing process, cost structure etc. then statistics Global and China key manufacturers Prefilled Syringes capacity production cost price profit production value gross margin etc information, and Global and China Prefilled Syringes capacity production market share supply demand shortage import export consumption etc data statistics, and Prefilled Syringes 2009-2014 capacity production price cost profit production value gross margin etc information.

Global Gynecological Cancers Market 2014-2018 (http://www.researchmoz.us/global-gynecological-cancers-market-2014-2018-report.html ) Analysts forecast the Global Gynecological Cancers market to grow at a CAGR of 12.47 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in prevalence of gynecological cancer. The Global Gynecological Cancers market has also been witnessing the emergence of personalized medicines. However, the increase in use of CAM could pose a challenge to the growth of this market. Global Gynecological Cancers Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Gynecological Cancers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Global and China Desensitizer Industry 2013 Market Research Report (http://www.researchmoz.us/global-and-china-desensitizer-industry-2013-market-research-report-report.html ) The report firstly introduced Desensitizer basic information included Desensitizer definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis, Desensitizer industry policy and plan, Desensitizer product specification, manufacturing process, cost structure etc. then statistics Global and China key manufacturers Desensitizer capacity production cost price profit production value gross margin etc information, and Global and China Desensitizer capacity production market share supply demand shortage import export consumption etc data statistics, and Desensitizer 2009-2014 capacity production price cost profit production value gross margin etc information.

And also listed Desensitizer upstream raw materials  and down stream analysis and Desensitizer marketing channels industry development trend and proposals. In the end, The report introduced Desensitizer new project SWOT analysis Investment feasibility analysis investment return analysis and also give related research conclusions and development trend analysis on China Desensitizer industry. 

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 6

1.2 List of Figures 7

2 Introduction 8

2.1 The Case for Innovation 8

2.1.1 Growing Opportunities for Biologic Products 8

2.1.2 Diversification of Molecular Targets 8

2.1.3 Innovative First-in-class Product Developments Remain Attractive 9

2.1.4 Changes in the Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Niche Indications 9

2.1.5 Sustained Innovation 10

3 Clinical and Commercial Landscape 11

3.1 Disease Overview 11

3.1.1 Disease Symptoms 12

3.1.2 Environmental Factors and Genetic Predisposition 12

3.1.3 Disease Pathophysiology 12

3.1.4 Pharmacotherapy Algorithm 13

3.2 Overview of Marketed Products for Rheumatoid Arthritis 14

3.3 Molecular Type Analysis 15

3.4 Molecular Target Analysis 16

3.4.1 Intracellular Therapeutic Targets 16

3.4.2 Membrane Therapeutic Targets 17

3.4.3 Extracellular Targets 17

3.5 Innovative Products in the RA Market 17

3.6 Efficacy and Safety of Marketed Products 20

3.7 Current Unmet Needs 22

4 Assessment of Pipeline Product Innovation 23

4.1 Rheumatoid Arthritis Pipeline by Molecule Type, Phase and Therapeutic Targets 23

4.2 Frequently Targeted Intracellular Kinases 25

4.2.1 p38 Kinase 25

4.2.2 MAPK 25

4.2.3 JAK 25

4.2.4 Spleen Tyrosine Kinase (Syk) 25

4.3 Frequently Targeted Cytokines and Receptors 26

4.3.1 TNF-α 26

4.3.2 Toll-Like Receptors 26

4.3.3 B Lymphocyte Stimulator 26

4.4 Efficacy and Safety of Pipeline Products 27

4.5 Comparative Distribution of Programs between the RA Market and Pipeline by Therapeutic Target Family 29

4.6 First-in-class Pipeline Programs Targeting Novel Molecule Targets 31

5 First-in-Class Target and Pipeline Program Evaluation 37

5.1 Cytokines and Receptors 37

5.1.1 Pipeline Programs which Target HMGB-1 37

5.1.2 Pipeline Programs which Target IL-10 Receptor 42

5.1.3 Pipeline Programs which Target HSP 60 46

5.1.4 Pipeline Programs which Target Interleukins 15 and 16 49

5.1.5 Pipeline programs which Target Macrophage Migration Inhibitory Factor (MIF) 52

5.2 Integrins 55

5.2.1 Pipeline Programs which Target Cadherin-11 55

5.2.2 Pipeline Programs which Target α1β1 Integrin (Very Late Antigen-1) 56

5.2.3 Pipeline Programs which Target Vascular Adhesion Protein-1 (VAP-1) 58

5.3 Proteases 59

5.3.1 Pipeline Programs which Target Cathepsin S 59

5.4 Nuclear Receptors 61

5.4.1 Pipeline Programs which Target RAR-Related Orphan Receptor (ROR) 61

5.4.2 Pipeline Programs which Target Nuclear Receptor Related 1 Protein 63

5.5 Intracellular Kinases 64

5.5.1 Pipeline Programs which Target Interleukin 1 Receptor Associated Kinase 4 64

5.6 Ion Channels 66

5.6.1 Pipeline Programs which Target Calcium Release Activated Channels 66

5.7 Others 68

5.7.1 Pipeline Programs which Target F1F0 ATP Synthase 68

5.7.2 Pipeline Programs which Target Immunoproteosome Subunit 7 (IMP7) 69

5.8 Conclusion 71

6 Deals and Strategic Consolidations 73

6.1 Licensing Deals 73

6.2 Co-development Deals 86

6.3 First-in-Class Programs which have not been involved in Licensing or Co-Development Deals 98

7 Appendix 99

7.1 Abbreviations 99

7.2 Methodology 102

7.3 References 102

7.4 References for Figures 5 and 8 109

7.5 Contact Us 111

7.6 Disclaimer 112

Explorer More Pharmaceutical Market Research Reports At:  http://www.researchmoz.us/pharmaceutical-market-reports-38.html

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:
90 Sate Street, Suite 700
Albany, NY 12207
Website@ http://www.researchmoz.us/
Blog: http://www.marketandresearch.org/
Blog: http://medicaldevicesmarket.blogspot.com/
Email: sales@researchmoz.us
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Source Article from http://ca.finance.yahoo.com/news/frontier-pharma-rheumatoid-arthritis-identifying-113000956.html
Frontier Pharma – Rheumatoid Arthritis: Identifying and Commercializing First-in-Class Innovation
http://ca.finance.yahoo.com/news/frontier-pharma-rheumatoid-arthritis-identifying-113000956.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results



コメントを残す

メールアドレスが公開されることはありません。 * が付いている欄は必須項目です

次のHTML タグと属性が使えます: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>